Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814610 | 0.86 | ROCK2 (0.41) | ROCK2ALDH1A1HTT | |
| SCHEMBL6817988 | 0.85 | NAMPT (0.43) | ROCK2RAB9AALDH1A1HTT | |
| SCHEMBL6818253 | 0.84 | ROCK2 (0.42) | ROCK2HTT | |
| SCHEMBL6708650 | 0.82 | ROCK2 (0.40) | EPHX1TBXA2RROCK2CYP1A2CYP2C19 | |
| SCHEMBL6814917 | 0.82 | AKR1C2 (0.48) | PLK1 | |
| SCHEMBL6710344 | 0.82 | EPHX1 (0.38) | EPHX1TBXA2RROCK2CYP1A2CYP2C19 | |
| SCHEMBL6833234 | 0.81 | KDM4C (0.43) | ROCK2RAB9AALDH1A1 | |
| SCHEMBL6835744 | 0.80 | ALB (0.43) | ROCK2ALDH1A1 | |
| SCHEMBL6835753 | 0.80 | ROCK2 (0.40) | ROCK2RAB9AALDH1A1 | |
| SCHEMBL6833880 | 0.78 | ALB (0.46) | ROCK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | EPHX1 1803/4885TBXA2R 343/4885PLK1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.